NewAmsterdam Pharma Company NV (NASDAQ:NAMS) shares, rose in value on Friday, January 24, with the stock price up by 1.72% to the previous day’s close as strong demand from buyers drove the stock to $23.60.
Actively observing the price movement in the last trading, the stock closed the session at $23.20, falling within a range of $22.78 and $24.13. The value of beta (5-year monthly) was -0.001. Referring to stock’s 52-week performance, its high was $27.29, and the low was $15.19. On the whole, NAMS has fluctuated by -7.45% over the past month.
With the market capitalization of NewAmsterdam Pharma Company NV currently standing at about $2.52 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.67M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NAMS’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 75% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of NAMS currently trading nearly -4.98% and 0.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.73, while the 7-day volatility ratio is showing 4.08% which for the 30-day chart, stands at 3.89%. Furthermore, NewAmsterdam Pharma Company NV (NAMS)’s beta value is -0.07, and its average true range (ATR) is 1.13.
A comparison of NewAmsterdam Pharma Company NV (NAMS) with its peers suggests the former has fared considerably weaker in the market. NAMS showed an intraday change of 1.72% in last session, and over the past year, it grew by 6.26%%.
Data on historical trading for NewAmsterdam Pharma Company NV (NASDAQ:NAMS) indicates that the trading volumes over the past 10 days have averaged 0.6 and over the past 3 months, they’ve averaged 850.34K. According to company’s latest data on outstanding shares, there are 92.17 million shares outstanding.
Nearly 43.32% of NewAmsterdam Pharma Company NV’s shares belong to company insiders and institutional investors own 35.47% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.97 million shares as on 2024-12-31, resulting in a short ratio of 2.3. According to the data, the short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 422.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 2.59 million. The stock has fallen by -8.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NAMS stock heading into the next quarter.
